Login / Signup

First-trimester miscarriage rate decreases with hydralazine therapy in pregnancies with early uterine vascular insufficiency: a cohort study.

Sergio LeibleAndrea CanalsRoderick WaltonGabriel MitelmanAngelo CastiglioneMiguel BironRosana FaundezWaldo Sepulveda
Published in: The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2021)
Hydralazine therapy in pregnancies with EUVI was associated with a significant decrease in the rate of miscarriage. We suggest a sequence of events leading to a higher risk of miscarriage in pregnancies with EUVI and propose a potential mechanism through which hydralazine may reduce this risk.
Keyphrases
  • preterm birth
  • gestational age
  • pregnancy outcomes
  • stem cells
  • mesenchymal stem cells
  • bone marrow